NAMS NewAmsterdam Pharma Co N.V.: institutional ownership and insider trading
200 funds reported holding $4.29B of NewAmsterdam Pharma Co N.V. in their latest 13F filings; in Q2 2026 funds net bought $12.4M, with 45 new positions and 19 funds selling out; over the last 12 months insiders bought $227K and sold $63.3M on the open market; over its last four quarters it reported revenue of $7.12M and net income of −$259M.
NAMS revenue and earnings
- Quarter ended Jun 30, 2026: revenue $3.70M, net income −$64.1M, EPS -0.52
- Quarter ended Mar 31, 2026: revenue $3.04M, net income −$48.4M, EPS -0.40
- Quarter ended Dec 31, 2025: revenue $32.0K, net income −$74.1M, EPS -0.62
- Quarter ended Sep 30, 2025: revenue $348K, net income −$72.0M, EPS -0.61
Famous investors holding NAMS
- Stanley Druckenmiller (Duquesne Family Office): $104M, 2.0% of the portfolio
- Lee Ainslie (Maverick Capital): $111M, 1.0% of the portfolio
- Andreas Halvorsen (Viking Global Investors): $142M, 0.4% of the portfolio
- Izzy Englander (Millennium Management): $17.0M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $23.2M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $4.09M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $407K, 0.0% of the portfolio
Largest institutional holders of NAMS
- Frazier Life Sciences Management, L.P. — $613M
- Capital World Investors — $414M
- FMR LLC — $350M
- RA CAPITAL MANAGEMENT, L.P. — $324M
- FCPM III SERVICES B.V. — $288M
- DEERFIELD MANAGEMENT COMPANY, L.P. — $145M
- VIKING GLOBAL INVESTORS LP — $142M
- Bain Capital Life Sciences Investors, LLC — $129M
- MAVERICK CAPITAL LTD — $111M
- Duquesne Family Office LLC — $104M
Recent NAMS insider trades
- Sep 30, 2026: Kastelein Johannes Jacob Pieter sold 50,246 shares ($1.26M)
- Sep 14, 2026: Davidson Michael H. bought 10,000 shares ($227K)
- Sep 4, 2026: Smither John W sold 1,600 shares ($40.5K)
- Aug 24, 2026: Kastelein Johannes Jacob Pieter sold 125,000 shares ($3.36M)
5%+ owners
- Capital World Investors: 10.4% (Schedule 13G/A, filed Jun 4, 2026)
- FMR LLC: 8.8% (Schedule 13G/A, filed Aug 6, 2026)
- Frazier Life Sciences Public Fund, L.P.: 8.7% (Schedule 13D/A, filed Sep 22, 2026)
Who owns the most NAMS stock?
The largest institutional holders of NewAmsterdam Pharma Co N.V. in the latest 13F filings are Frazier Life Sciences Management, L.P. ($613M), Capital World Investors ($414M), FMR LLC ($350M).
Are insiders buying or selling NAMS?
Over the last 12 months insiders bought $227K and sold $63.3M of NewAmsterdam Pharma Co N.V. stock on the open market (SEC Form 4).
Which famous investors own NAMS?
Stanley Druckenmiller, Lee Ainslie, Andreas Halvorsen, Izzy Englander, Ken Griffin.
What was NAMS's revenue last quarter?
NewAmsterdam Pharma Co N.V. reported revenue of $3.70M for the quarter ended June 30, 2026, with net income of −$64.1M.
Which ETFs hold NAMS?
11 ETFs and mutual funds hold it among their top 100 positions, including INDCX, SBIO, MXMSX, KCSIX.